v3.25.4
Segment Reporting (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2025
USD ($)
segment
Dec. 31, 2024
USD ($)
Segment Reporting    
Number of reportable segment | segment 1  
Number of operating segment | segment 1  
External R&D expense $ 208,440 $ 184,550
Equity-based compensation expense 75,600 36,628
Depreciation and amortization expense 1,658 1,937
Other non-operating expense/(income), net (301) (85)
Net loss 377,939 246,294
Operating segment    
Segment Reporting    
Employee related expense 119,262 68,790
External expense - G&A 56,083 22,384
Other segment items $ 24,187 $ 19,383
Description-Other segment related expense Consists of other segment expenses related to supplies, corporate and facilities expenses Consists of other segment expenses related to supplies, corporate and facilities expenses
Equity-based compensation expense $ 75,600 $ 36,628
Depreciation and amortization expense 1,657 1,937
Other non-operating expense/(income), net (6,706) (5,760)
Net loss 377,939 246,294
Operating segment | Apitegromab    
Segment Reporting    
External R&D expense 89,802 78,290
Operating segment | SRK-181    
Segment Reporting    
External R&D expense 2,408 9,957
Operating segment | SRK-439    
Segment Reporting    
External R&D expense 8,969 11,638
Operating segment | Early research and other    
Segment Reporting    
External R&D expense $ 6,677 $ 3,047